Reported Earnings • Mar 20
Full year 2025 earnings released: ₩2,340 loss per share (vs ₩1,547 loss in FY 2024) Full year 2025 results: ₩2,340 loss per share (further deteriorated from ₩1,547 loss in FY 2024). Revenue: ₩16.7b (down 5.4% from FY 2024). Net loss: ₩11.9b (loss widened 51% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. 공지 • Mar 07
HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026 HLscience Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea Reported Earnings • Mar 22
Full year 2024 earnings released: ₩1,547 loss per share (vs ₩270 loss in FY 2023) Full year 2024 results: ₩1,547 loss per share (further deteriorated from ₩270 loss in FY 2023). Revenue: ₩17.7b (down 31% from FY 2023). Net loss: ₩7.88b (loss widened 472% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. 공지 • Mar 08
HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025 HLscience Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 89, anyangpangyo-ro, gyeonggi-do, uiwang South Korea New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩64.2b market cap, or US$44.7m). New Risk • Sep 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 110% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩87.4b market cap, or US$65.8m). Reported Earnings • Mar 21
Full year 2023 earnings released: ₩270 loss per share (vs ₩304 profit in FY 2022) Full year 2023 results: ₩270 loss per share (down from ₩304 profit in FY 2022). Revenue: ₩25.6b (down 52% from FY 2022). Net loss: ₩1.38b (down 186% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. New Risk • Jul 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 50% over the past year. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩103.1b market cap, or US$79.2m). Reported Earnings • Mar 26
Full year 2022 earnings released: EPS: ₩304 (vs ₩2,608 in FY 2021) Full year 2022 results: EPS: ₩304 (down from ₩2,608 in FY 2021). Revenue: ₩52.8b (down 50% from FY 2021). Net income: ₩1.59b (down 88% from FY 2021). Profit margin: 3.0% (down from 13% in FY 2021). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩23,400, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total loss to shareholders of 51% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.3%). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공지 • Sep 30
HLscience Co., Ltd. (KOSDAQ:A239610) announces an Equity Buyback for KRW 3,000 million worth of its shares. HLscience Co., Ltd. (KOSDAQ:A239610) announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares according to the contract with Mirae Asset Daewoo Securities. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on October 04, 2023. As of September 29, 2022, the company had 145,575 and 0 treasury stock holdings in acquisition within the scope of allotment and through other acquisition, respectively. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 17x in the Personal Products industry in South Korea. Total loss to shareholders of 65% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Is New 90 Day High Low • Feb 26
New 90-day low: ₩40,900 The company is down 3.0% from its price of ₩42,238 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 13% over the same period. 공지 • Feb 06
HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021 HLscience Co., Ltd., Annual General Meeting, Mar 23, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Dec 28
New 90-day high: ₩47,700 The company is up 1.0% from its price of ₩47,050 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 12% over the same period. Upcoming Dividend • Dec 22
First Dividend Is ₩400 Per Share Will be paid on the 21st of April to those who are registered shareholders by the 29th of December. This is the first dividend for HLscience since going public. The average dividend yield among industry peers is 0.6%. Is New 90 Day High Low • Oct 16
New 90-day low: ₩44,000 The company is down 22% from its price of ₩56,300 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 6.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: ₩44,550 The company is down 18% from its price of ₩54,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 10.0% over the same period.